Results 181 to 190 of about 4,754 (217)
Some of the next articles are maybe not open access.
Antimony Excretion in a Patient with Renal Impairment During Meglumine Antimoniate Therapy
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2000Meglumine antimoniate was administered to a patient with visceral leishmaniasis with normal renal function. Soon after the first intramuscular administration of meglumine antimoniate 20 mg/kg, equivalent to 510 mg antimony (Sb), the patient developed septic shock with oliguria. Creatinine clearance decreased to 23 ml/minute. Treatment was discontinued,
P, Hantson +3 more
openaire +2 more sources
Cytogenetic Observations After Meglumine Antimoniate Therapy for Visceral Leishmaniasis
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1996Few data are available concerning the genotoxic effects of antimonial salts therapy in humans. A patient suffering from visceral leishmaniasis was treated for 15 days with a cumulative dose meglumine antimoniate 42.5 g. Peripheral blood lymphocytes sampled before treatment, 7 days later, and at the end of therapy (day 15) were examined for the presence
P, Hantson +6 more
openaire +2 more sources
Developmental toxicity of meglumine antimoniate and transplacental transfer of antimony in the rat
Reproductive Toxicology, 2006Meglumine antimoniate (MA), a pentavalent antimonial (SbV) drug, has been used for the treatment of leishmaniases for over half a century but there is almost no data on its safety and kinetics during pregnancy. This study was undertaken to investigate the developmental toxicity of MA as well as the transplacental transfer of antimony (Sb) in rats ...
Elaine S, Miranda +3 more
openaire +2 more sources
Weekly vs. fortnightly intralesional meglumine antimoniate in cutaneous leishmaniasis
International Journal of Dermatology, 1999One hundred and four patients with a clinical diagnosis of cutaneous leishmaniasis (CL) and a positive Giemsa‐stained smear for the parasite were recruited after informed consent into this randomized clinical trial, comparing the efficacy of weekly vs. fortnightly intralesional injections of meglumine antimoniate. Patients having more than five lesions
Ghulam Mujtaba +5 more
openaire +2 more sources
Safety profile of meglumine antimoniate intralesional infiltration for cutaneous leishmaniasis
Expert Review of Anti-infective Therapy, 2020Objectives: Cutaneous leishmaniasis is a neglected disease, associated with high morbidity, which is partially due to the toxicity of available therapies. The pentavalent antimonial derivatives intralesional infiltration has proven to be as effective as the intravenous drug-based therapy, however, there is a lack of robust safety data.Methods: Phase II,
Herbert J. Fernandes +5 more
openaire +2 more sources
Transactions of the Royal Society of Tropical Medicine and Hygiene, 1988
5 patients with visceral leishmaniasis were treated with sodium stibogluconate (2 patients) or meglumine antimoniate (3 patients) given intramuscularly at a dose of 10 mg antimony (Sb) per kg body weight daily for 30 d. Blood samples were obtained at intervals during treatment and blood Sb concentrations measured by anodic stripping voltametry.
J D, Chulay, L, Fleckenstein, D H, Smith
openaire +2 more sources
5 patients with visceral leishmaniasis were treated with sodium stibogluconate (2 patients) or meglumine antimoniate (3 patients) given intramuscularly at a dose of 10 mg antimony (Sb) per kg body weight daily for 30 d. Blood samples were obtained at intervals during treatment and blood Sb concentrations measured by anodic stripping voltametry.
J D, Chulay, L, Fleckenstein, D H, Smith
openaire +2 more sources
Meglumine antimoniate, amiodarone and torsades de pointes: a case report
Resuscitation, 1999Pentavalent antimonial drugs used for the treatment of leishmaniasis have been associated with sudden deaths, probably due to the development of ventricular tachyarrhythmias. Prolongation of the QT interval and ventricular tachyarrhymias have been described in patients on amiodarone therapy.
I, Segura, I, García-Bolao
openaire +2 more sources
COMPARISON OF MEGLUMINE ANTIMONIATE AND PENTAMIDINE FOR PERUVIAN CUTANEOUS LEISHMANIASIS
The American Journal of Tropical Medicine and Hygiene, 2005Pentamidine was compared with meglumine antimoniate (Glucantime) for 80 patients with cutaneous leishmaniasis due to Leishmania braziliensis in Peru. Of the 40 patients administered Glucantime (20 mg of antimony [Sb]/kg/day intravenously for 20 days), 31 cured (78%), 6 failed (15%), of which 5 were due to relapse, and 3 were lost to follow-up (7%).
Ellen M, Andersen +7 more
openaire +2 more sources
BioMetals, 2006
It has been shown previously that Sb(V) forms mono- and bis-adducts with adenine and guanine ribonucleosides, suggesting that ribonucleosides may be a target for pentavalent antimonial drugs in the treatment of leishmaniasis. In the present work, the reactions of antimoniate (KSb(OH)(6)) and meglumine antimoniate (MA) with guanosine 5'-monophosphate ...
Cláudio, dos Santos Ferreira +3 more
openaire +2 more sources
It has been shown previously that Sb(V) forms mono- and bis-adducts with adenine and guanine ribonucleosides, suggesting that ribonucleosides may be a target for pentavalent antimonial drugs in the treatment of leishmaniasis. In the present work, the reactions of antimoniate (KSb(OH)(6)) and meglumine antimoniate (MA) with guanosine 5'-monophosphate ...
Cláudio, dos Santos Ferreira +3 more
openaire +2 more sources
Systemic meglumine antimoniate‐induced severe dilated cardiomyopathy
Dermatologic Therapy, 2022Nesrine Ben Salah +6 more
openaire +2 more sources